7700 E Arapahoe Rd., Centennial, 80112-1268, CO, USA medicalsciences@onlinescientificresearch.info

Progress in Medical Sciences ISSN: 2577 - 2996

Video Article

Impact Factor: 1.023*

Progress in Medical Sciences. 2021; 5(1):(41-113)

Correlation between Platelet Count, TSH and Thyroxine in a Patient Presenting with Myxedema

Zohra Malik* and Zareen Razaq


Myxedema is a very rare and life threatening endocrine emergency which results from severe hypothyroidism

and effects almost every organ system. We-hereby-present a 64-year-old-woman with PMH

of hypothyroidism, liver cirrhosis, DM, HLD who presented to our ED because of altered mental status

and dizziness. Patient reported feeling ill for the last two days, appeared lethargic, and responded

slowly to questions. She denied headache, fever, changes in vision/smell, neck pain, chest pain, cough/

wheezing, abdominal pain, bowel or urinary symptoms. On arrival to the ED, patient was hypothermic

with temperature of 93.2 F, hypotensive with blood pressure of 99/49 mm Hg, heart rate of 53 beats per

minute and respiratory rate of 15 breaths per minute. On examination, the patient was lethargic, confused

at times, heart sounds regular, no murmurs, soft, non-tender ab-domen, no significant findings on neck

exam. Laboratory work-up was significant for white cell count of 2.6 L x 103/uL, Hb 11.6 g/dL, HCT 33.8%,

platelet count 53 x 103/uL, TSH at presentation 73.30 mIU/L, free T4 was 0.12 ng/dL. Patient was treated

with 200 mcg of IV levothyroxine, 10 mcg of leothyronine, 100 mg of hydrocortisone. In the ED, patient

was given broad spectrum anti-biotics for the possibility of an infection triggering her myxedema. Over

the course of days, it was observed that as the TSH trended down, the thyroid hormone level increased

and the platelets trended up.

Trend in TSH (mIU/L), Free thyroxine (ng/dL) and platelets (x 103/uL) in our patient.

Day 1 73.30 0.12 53

Day 3 34.50 0.33 58

Day 5 27.40 0.35 70

Day 7 24.20 0.60 77

Day 10 7.85 0.88 103

There seemed to be an association with elevated TSH, low thyroxine and low platelets. The low platelets

were very concerning to us. But we found that as the myxedematous state of our patient improved with

a decreasing TSH and increasing T4, the platelet count got better. It’s not the throm-bocytopenia that we

need to treat. It’s the Myxedematous state that we need to address and the he-matological abnormality

corrects itself. As the TSH and the thyroid hormones normalize, the plate-lets correct themselves. One

possible mechanism through which thyroid hormones may increase the number of megakaryocytes is

the modulation of bone marrow matrix proteins, such as fibronectin [1, 2]. Thyroid hormones increase

the expression of fibronectin gene. Individuals with hyperthy-roidism have elevated blood levels of

fibronectin [1, 2]. Fibronectin appears to affect megakaryo-cyte maturation and thrombopoiesis through

interaction with integrin α4β1 [3]. Apoptosis is the major mechanism through which platelets die and

thyroid hormones have been shown to inhibit apoptosis in several cell lines [4].

Thrombocytopenia can be part of a multisystem complication of myxedema which corrects as the thyroid

functions normalizes.